Core Viewpoint - The Shanghai Stock Exchange has decided to terminate the review of Xiamen Municipal Environmental Energy Co., Ltd.'s application for an initial public offering (IPO) and listing on the main board after the company and its sponsor, Haitong Securities Co., Ltd., submitted a request to withdraw the application [1][2]. Company Overview - Xiamen Environmental Energy's main business includes waste-to-energy power generation from municipal solid waste, hazardous waste disposal, medical waste disposal, kitchen waste disposal, leachate treatment, ecological landfill, marine sanitation, and garbage compression transfer, forming a profit model primarily based on income from municipal waste treatment, hazardous waste disposal, and comprehensive environmental treatment [2]. Shareholding Structure - As of the signing date of the prospectus, Xiamen Municipal Group directly holds 83.99% of the company's shares, with an additional 2.96% held indirectly through Xiamen Municipal Songhu, totaling 86.95% ownership. The actual controller of the company is the Xiamen State-owned Assets Supervision and Administration Commission, which directly holds 100% of Xiamen Municipal Group [2]. Fundraising Plans - Xiamen Environmental Energy initially planned to raise 1.096 billion yuan (approximately 109,650.56 million yuan) for various projects, including the third phase of the Eastern (Xiang'an) waste-to-energy power plant, the first phase of the Ninghua County waste-to-energy power plant construction project, the establishment of the Xiamen Environmental Energy R&D center, and to supplement working capital [3][4]. Investment Breakdown - The total investment for the projects is approximately 1.658 billion yuan (165,866.96 million yuan), with the planned fundraising amount of 1.096 billion yuan allocated as follows: - Eastern (Xiang'an) waste-to-energy power plant phase III: 789.34 million yuan (30 million yuan to be raised) - Ninghua County waste-to-energy power plant phase I: 339.82 million yuan (26.7 million yuan to be raised) - Xiamen Environmental Energy R&D center: 200.55 million yuan (fully funded by the raised amount) - Supplementing working capital: 328.95 million yuan (fully funded by the raised amount) [4].

2024年，A股市场跌宕起伏，9月后，在一揽子政策利好的推动下，A股市场情绪得到显著提振，券商业绩整体回升。 3月28日，中国证券业协会发布券商2024年度经营数据，证券公司未经审计财务报表显示，150家证券公司2024年度实现营业收 入4511.69亿元，实现净利润1672.57亿元。2024年券商的营收和净利润创下了近三年新高。 在22家已披露2024年成绩单的上市券商中，有17家归母净利润同比增长，占比接近八成，仅有中金公司、光大证券、中泰证 券、信达证券和国联民生证券五家券商净利同比下滑。 值得关注的是，中信证券、华泰证券、国泰君安、招商证券和中国银河五家头部券商归母净利润超过百亿元，其中国泰君安、 招商证券和中国银河等三家券商2024年重新回到"净利百亿俱乐部"。此外，广发证券和东方财富归母净利润也均超95亿元，接 近百亿元。 "2024年，公司大力提升三种能力，分别是持续增强服务的专业性，不断提升业务的协同性和深入强化战略的敏捷性。"国泰君 安董事长朱健表示，2025年，公司要努力实现四个跨越，为建设具备国际竞争力和市场引领力的一流投资银行奠定坚实基础。 | | | | 归属母公司股东的净利润 | ...

Investment Philosophy - The essence of investment is to manage desires, with a focus on "slowly becoming rich" rather than seeking quick gains [3][4] - Emphasis on understanding major variables and market trends, advocating for a "less is more" approach in research [2][3] Chinese Economic Outlook - "Intelligent manufacturing" is seen as a new engine for China's economic development, crucial for the transition from old to new economic drivers [4][5] - The real estate sector currently accounts for approximately 25% of GDP, while strategic emerging industries contribute around 15% [4] - Service consumption, currently at about 20%, is identified as a potential growth area, especially with advancements in AI [4] Market Dynamics - The second quarter of the year is viewed as a critical observation period for policy impacts on both the US and global economies [6][7] - The narrative of "East rising, West falling" is challenged, suggesting a more nuanced view of global economic interdependence [6][7] - The US economy's performance, which constitutes 26.1% of global GDP, significantly influences global market dynamics [7]

中国经济网北京3月31日讯复洁环保(688335.SH)近日披露2024年年度报告。 复洁环保首次公开发行股票募集资金总额为8.41亿元，扣除发行费用后，募集资金净额为7.64亿元。复 洁环保最终募集资金净额较原计划多2.63亿元。复洁环保于2020年8月11日发布的招股说明书显示，该 公司计划募集资金5.00亿元，分别用于低温真空脱水干化成套技术装备扩建项目、环保技术与设备研发 新建项目、补充流动资金。 复洁环保首次公开发行股票的保荐机构为海通证券，保荐代表人为钮嘉、金涛。复洁环保上市发行费用 为7749.21万元，其中保荐及承销费用5838.14万元。 复洁环保2023年半年度权益分派实施公告显示，本次转增股本以方案实施前的公司总股本101,860,511股 为基数，以资本公积金向全体股东每股转增0.45股，共计转增45,837,230股，本次分配后总股本为 147,697,741股。 复洁环保2022年半年度权益分派实施公告显示，该次转增股本以方案实施前的公司总股本72,521,508股 为基数，以资本公积金向全体股东每股转增0.4股，共计转增29,008,603股，本次分配后总股本为 101,530, ...

| | | | 2 | 华泰联合 | 3 | | --- | --- | --- | | 2 | 中信证券 广司 | TITU 3 | | 4 | 、东兴证券TONWOOD TREE | | | 4 | 申万宏源 | 2 | | 4 | 中信建投 | 2 | | 7 | 华安证券 | 1 | | 7 | 广发证券 | 1 | | 7 | 国元证券 | 1 | | 7 | 平安证券 | 1 | | 7 | 申港证券 | 1 | | | 天风证券 | 1 | | 7 | 招商证券 | 1 | | 76 | 中金公司 | FOT 1 . | | 1 | 中国银河TONW( | on TREE | | 7 | 中泰证券 | 1 | | 7 | 中银国际 | 1 | | | 信计 | 27 | 二、律师事务所业绩排名 2025年1-3月，共有16家律师事务所为这27家新上市公司IPO提供了法律服务。 文/梧桐数据中心 随着3月28日开发科技（920029）在北交所上市，2025年1-3月A股合计新上市公司27家，其中沪市主板4家、科创板5家、深市主板3家、创业板12家、北交所3家。 相较去年同期的30家，同比下降10% ...

Core Viewpoint - The report provides a comprehensive overview of the Hai Futong CSI 2000 Enhanced Strategy ETF's performance and management strategies for the year 2024, highlighting its investment objectives, strategies, and financial results. Fund Overview - The fund is named Hai Futong CSI 2000 Enhanced Strategy ETF, managed by Hai Futong Fund Management Co., Ltd., and its contract became effective on March 27, 2024 [2]. - The fund aims to achieve a net asset value growth rate that does not deviate from its benchmark (CSI 2000 Index) by more than 0.35% on a daily average and seeks to outperform the benchmark [2][4]. Investment Strategies - The fund employs a combination of quantitative investment analysis and fundamental research to manage its portfolio actively [2]. - Key investment strategies include stock investment, bond investment, convertible bonds, asset-backed securities, stock index futures, and options [2][4]. Financial Performance - As of December 31, 2024, the fund reported a realized loss of approximately 6.35 million RMB and a total profit of about 6.75 million RMB [3]. - The weighted average net value profit rate for the period was -21.66%, while the fund's net asset value growth rate was 18.89% [3][4]. - The fund's net asset value at the end of the reporting period was approximately 12.28 million RMB, with a per share net value of 1.1889 RMB [3]. Market Context - The report indicates that the Chinese economy showed signs of weak recovery driven by policy measures, with a projected GDP growth of 5% for 2024 [9]. - The A-share market experienced fluctuations, with the Shanghai Composite Index rising by 12.7% and the CSI 300 Index increasing by 14.7% during the year [10]. Management Insights - The fund management team actively adjusted investment models to adapt to market changes, incorporating industry and style models to identify investment opportunities [11]. - The fund's net value growth rate of 18.89% significantly outperformed the benchmark's return of 10.32% during the reporting period [12]. Compliance and Governance - The fund management company emphasizes compliance with legal regulations and internal controls to ensure the protection of investors' interests [15]. - The management has implemented measures to enhance compliance culture and risk awareness among employees [15].

Core Viewpoint - The company, Maiwei Biotech, is facing significant financial challenges, including a net loss of approximately 106.96 million yuan, primarily due to high R&D expenditures and the short market presence of its products [2][10][11]. Financial Performance - The company's net profit attributable to shareholders was -104.39 million yuan, with a net loss excluding non-recurring items of -106.96 million yuan, indicating a slight increase in losses compared to the previous year [10][18]. - Revenue for the year reached 199.78 million yuan, a 56.28% increase from the previous year, driven by a significant rise in drug sales [18][26]. - R&D expenses for the year were approximately 78.29 million yuan, reflecting a decrease of 6.33% compared to the previous year [10][18]. Product Development and Market Position - The company has three products on the market: Junmaikang®, Mailishu®, and Maiweijian®, with ongoing clinical trials for several innovative drugs [10][11][26]. - The company has a pipeline of 16 products at various stages, including 12 innovative drugs and 4 biosimilars, focusing on oncology and age-related diseases [10][11]. - The sales revenue from the drug Deshu Single Antibody reached approximately 138.97 million yuan, marking a 230.17% increase year-on-year [26][27]. Regulatory and Compliance - The company is subject to stringent regulatory oversight, with compliance to various national and local drug management regulations impacting its operations [14][15]. - The company has established internal systems to ensure compliance with legal and regulatory requirements, including information disclosure obligations [4][5]. R&D and Innovation - The company emphasizes innovation, with a focus on developing differentiated products and maintaining a robust R&D pipeline [20][21]. - The company has established multiple technology platforms to enhance its drug discovery and development processes, contributing to its competitive edge in the market [20][21]. Market Strategy - The company is expanding its commercial sales efforts, with a focus on building a professional sales and marketing team to enhance product promotion and market penetration [25][28]. - The marketing strategy is centered around a patient-centric approach, leveraging clinical data to educate healthcare providers and patients about its products [28].

Summary of Key Points Core Viewpoint The company, Maiwei (Shanghai) Biotechnology Co., Ltd., is seeking to provide a guarantee of up to RMB 3.1 billion for its wholly-owned subsidiaries to support their financing needs, which is subject to approval by the shareholders' meeting [1][2][14]. Group 1: Guarantee Overview - The total guarantee amount for the subsidiaries is expected to be no more than RMB 3.1 billion, with specific amounts and terms to be finalized in formal agreements [1][2]. - The subsidiaries include Jiangsu Taikang Biomedical Co., Ltd., Shanghai Langrun Maiwei Biomedical Technology Co., Ltd., Jiangsu Maiwei Pharmaceutical Co., Ltd., Jiangsu Maiwei Kangxin Drug Research and Development Co., Ltd., Maiwei (Chongqing) Biomedical Co., Ltd., and Maiwei Vision Pharmaceutical Technology (Zhejiang) Co., Ltd. [1][2]. Group 2: Financial Performance of Subsidiaries - Jiangsu Taikang Biomedical Co., Ltd. reported total assets of RMB 303.29 million and total liabilities of RMB 332.95 million as of December 31, 2024, with a net loss of RMB 2.37 million [3]. - Shanghai Langrun Maiwei Biomedical Technology Co., Ltd. had total assets of RMB 118.89 million and total liabilities of RMB 70.66 million, with a net loss of RMB 5.31 million [6]. - Jiangsu Maiwei Pharmaceutical Co., Ltd. reported total assets of RMB 41.57 million, total liabilities of RMB 35.65 million, and a net profit of RMB 8.77 million [9]. Group 3: Approval Process - The proposal for the guarantee has been approved by the board of directors and will be submitted to the shareholders' meeting for final approval [2][14]. - The decision-making process complies with relevant laws and regulations, ensuring no harm to the interests of the company and its shareholders [14][16]. Group 4: Risk Management - The company believes that the subsidiaries have good credit status, which allows for effective control and mitigation of guarantee risks [14]. - The independent directors and supervisory board have expressed support for the guarantee, emphasizing its necessity for the subsidiaries' operational needs [14].

Summary of Key Points Core Viewpoint - The company has completed the investment project "Annual Production of 1,000kg Antibody Industrialization Construction Project" and plans to permanently supplement its working capital with the remaining raised funds, which aligns with its operational needs and long-term development strategy [9][10]. Fundraising Basic Information - The total amount raised by the company was RMB 3,476,520,000, with a net amount of RMB 3,303,432,172.40, all of which was received by January 10, 2022 [1][2]. Fund Management and Usage - The company established special accounts for managing the raised funds, which are stored in accounts approved by the board of directors, ensuring investor protection [2]. - As of February 28, 2025, the remaining balance of the raised funds for the "Annual Production of 1,000kg Antibody Industrialization Construction Project" was RMB 29,204,764.93 [4][6]. Project Completion and Fund Surplus - The project has been completed as of December 31, 2024, and the remaining funds will be used to enhance operational efficiency [6][9]. - The surplus funds amounting to RMB 18,944.20 million will be permanently added to the working capital [10]. Reasons for Fund Surplus - The surplus was primarily due to prudent fund management, effective cost control, and the use of self-owned funds and bank loans for project expenses, leading to a certain amount of surplus [7][9]. Future Fund Usage Plan - The company plans to use the surplus funds to support daily operations, ensuring efficient use of the raised funds [8][10]. Review and Approval Process - The decision to conclude the investment project and reallocate surplus funds has been approved by the board of directors and the supervisory board, and will be submitted for shareholder meeting approval [10][11].

海通证券股份有限公司 关于峰岹科技（深圳）股份有限公司 海通证券股份有限公司（以下简称"海通证券"或"保荐机构"）作为峰岹 科技（深圳）股份有限公司（以下简称"峰岹科技"或"公司"）首次公开发行 股票并在科创板上市的持续督导保荐机构，根据《证券发行上市保荐业务管理办 法》《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》 《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自律 监管指引第 1 号——规范运作》等相关规定，对峰岹科技 2024 年度募集资金存 放与实际使用情况的事项进行了核查，具体情况及核查意见如下： 一、募集资金基本情况 （一） 实际募集资金金额、资金到账时间 经中国证券监督管理委员会《关于同意峰岹科技（深圳）股份有限公司首次 公开发行股票注册的批复》（证监许可2022457 号）并经上海证券交易所同意， 公司首次向社会公众公开发行人民币普通股（A 股）2,309.0850 万股，发行价格 为人民币 82 元/股，募集资金总额为人民币 189,344.97 万元，扣除发行费用合计 人民币 16,498.79 万元（不含增值税）后，实际募集资金净额为人民币 1 ...